Medical device company Centinel Spine saw record revenue and growth in 2022, achieving the No. 2 total disc replacement market position globally.
The company attributes a large part of its growth to its Prodisc product line, which includes new products such as the Prodisc L Lumbar for total disc replacements, the Prodisc C Vivo and the Prodisc C SK for cervical total disc replacements.
Centinel's full-year revenue hit $45 million in 2022, driven by C Vivo and C SK, according to a May 2 press release. The Prodisc L saw a 12 percent growth in total surgeon users in 2022 compared to the year before.
The Prodisc L business also saw a 26 percent growth due to the full release of the novel Prodisc L anatomic implant designs, increasing patient awareness of total disc replacement as an alternative to fusion and broader reimbursement coverage from major payers, including Aetna.
Prodisc products are currently in use by 500 surgeons at almost 600 hospitals and ASCs nationwide, with revenue growth in the ASC space up by 80 percent from the previous year.